Treatment of papillomavirus-associated lesions using...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/20 (2006.01) A61K 31/70 (2006.01) A61K 39/12 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2215525

Interleukin-12 (IL-12) or a functional analogue thereof, or a polynucleotide encoding IL-12 or encoding a functional analogue thereof, is used as a therapeutic material or adjuvant in treating papillomavirus-associated lesions e.g. warts due to HPV 6 and/or 11, e.g. condylomaacuminata. IL-12 or a vector encoding it for endogenous production can be used together with a vaccine such as a papillomavirus antigen, or a vector encoding a papillomavirus antigen.

On utilise l'interleukine-12 (IL-12) ou un de ses analogues fonctionnels, ou encore un polynucléotide codant l'interleukine-12 ou codant un de ses analogues fonctionnels, comme substance thérapeutique ou comme adjuvant dans le traitement de lésions liées au virus du papillome, notamment de verrues causées par le virus du papillome humain (VPH) 6 et/ou 11, notamment le condylome acuminé. Pour développer une production l'IL-12 ou un vecteur en codant la production endogène peut s'utiliser en association avec un vaccin tel qu'un antigène du papillome, ou un vecteur codant un antigène du papillome.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Treatment of papillomavirus-associated lesions using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of papillomavirus-associated lesions using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of papillomavirus-associated lesions using... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2042773

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.